Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pediatric Oncology
•
Medical Oncology
•
Hematology
•
Sickle Cell
•
Plasma exchange
•
Benign Hematology
Would you ever consider depleting alloantibodies using plasma exchange to allow for partially matched RBC exchange in sickle cell patients with critically severe acute chest?
Related Questions
For patients with incidental findings of venous thromboembolism during workup of a treatable malignancy, how do you approach discontinuation after the treatment is complete?
What is the ideal period to wait until curative surgery for patients with acute pulmonary embolism and solid malignancy?
What would your next line of treatment be for a patient with Hb SC with history of recurrent VOC and new bone infarct who is already on hydroxyurea and phlebotomy?
What is your strategy for optimizing hydroxyurea dosage in patients with symptomatic sickle cell disease, particularly for genotypes HbSS and HbS/Beta thal?
What is your target Hgb/Hct for women who are pregnant and have sickle cell disease in whom you are doing scheduled transfusions?
How do you manage hyperalgesia in patients with sickle cell disease?
Is there any indication for hydroxyurea in patients with sickle cell trait?
What subset of sickle cell disease patients are you offering sickle cell disease gene therapy?
Is there a correlation between spleen size and degree of thrombocytopenia?
Would you anticoagulate a patient with splenic infarctions in the setting of CMV viremia?